Shingrix logo

Product menu

Woman in her 50s jogging in a picturesque autumnal park
Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.1,2

There is a 1 in 4 lifetime risk of the dormant varicella-zoster virus reactivating and causing shingles.3

SHINGRIX is specifically formulated to address the age-related decline in varicella-zoster virus-specific immunity.1,4-6

SHINGRIX generates a strong and sustained immune response to help protect your patients 50 years of age and older from developing shingles.1,4-8

Prescribing information (GB)

Download

Prescribing information (NI)

Download

As age increases, varicella-zoster virus-specific cellular immunity declines, leading to an increased risk of developing shingles.1

Visual representation using chevrons to show the age-related decline in immunity’s link to herpes zoster. As age increases, varicella zoster virus-specific cellular immunity declines leading to an increased risk of developing shingles. Visual representation using chevrons to show the age-related decline in immunity’s link to herpes zoster. As age increases, varicella zoster virus-specific cellular immunity declines leading to an increased risk of developing shingles.

Do you know the impact shingles could have on your patients older than 50 years of age?

90% of adults in the UK are infected with the virus that causes shingles.9

There is a 1 in 4 lifetime risk of the dormant varicella-zoster virus reactivating and causing shingles.3

A herpes zoster rash on the left-hand side of a patient’s back.
Close up of a herpes zoster rash.

Images above show patient examples of shingles induced unilateral vesicular (fluid filled blisters) rash.

Post-herpetic neuralgia (PHN)

Following the rash, persistent pain at the site, known as PHN, can develop and is seen more frequently in older people. Pain that persists for, or appears more than 90 days after the onset of rash is a commonly accepted definition for PHN.3

Affects about 20% of patients with shingles and is the most common complication of shingles.2

PHN can last from three to six months, but can persist for longer.3

Other complications may also occur.

Ocular: Herpes zoster ophthalmicus affects approximately 10-20% of patients with shingles.10

Cutaneous: e.g. bacterial superinfection, scarring.11

Neurological: e.g. hearing/sensory loss, transverse myelitis, cranial/peripheral nerve palsies.11

Visceral: e.g. bronchitis, peritonitis.11

SHINGRIX is the first and only non-live shingles vaccine to combine a recombinant antigen with an adjuvant system generating a strong and sustained immune response in adults 50 years of age and older.4-8

Visual representations of the a scientific design of SHINGRIX. Showing the antigen (glycoprotein E) and the adjuvant system (AS01B). Visual representations of the a scientific design of SHINGRIX. Showing the antigen (glycoprotein E) and the adjuvant system (AS01B).

Learn more about SHINGRIX

Red circular icon, showing greater than 90% efficacy against herpes zoster

How efficacious is SHINGRIX?

SHINGRIX demonstrated >90% efficacy against shingles in adults 50 years of age and older based on pooled data from two large, phase 3 randomised controlled trials.4,5,7,8

review efficacy data

Red patient icon, 4 patient figures, 1 of the 4 coloured grey

Who can benefit from SHINGRIX?

There is a 1 in 4 lifetime risk of developing shingles.3 Age-related decline in immunity puts patients 50 years of age and older at an increased risk of developing shingles.1,2

View Patient Profiles

Red safety icon, white plus on a red circular background

Learn more about the safety profile of SHINGRIX

The majority of local and systemic adverse reactions were mild to moderate and transient, based on two large, phase 3 randomised controlled trials. Reactions reported as severe lasted 1 to 2 days.4,5,7,8

Explore safety data

References

  1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356 (13): 1338-43.
  2. Gauthier et al. Epidemiology and costs of herpes zoster and postherpetic neuralgia in the United Kingdom . Epidemiol infecti. 2009; 137: 38-472.
  3. DH Green Book ch 28a - Shingles. February 2016. Accessed July 2021
  4. Shingrix, GB Summary of Product Characteristics (SPC)
  5. Shingrix, NI Summary of Product Characteristics (SPC)
  6. Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar; 32 (15): 1745-53.
  7. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372 (22): 2087-96.
  8. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375 (11): 1019-32.
  9. DH Green Book ch 34 Varicella pg 422. August 2015. Accessed July 2021
  10. Johnson et al. 2015. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Vol. 3 (4): 109–120
  11. Volpi A. Severe complications of herpes zoster. Herpes. 2007 Sep;14 Suppl 2: 35-9.
  12. Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012 Apr;30 (20): 3126-35.
  13. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1 /2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012 Oct;206 (8): 1280-90.
  14. Crooke, S.N., et al.Immun Ageing. 2019 Sep 13; 16:25.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

PM-GB-SGX-WCNT-210007
Date of preparation: July 2021
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.